Accretion Nutraveda
Accretion Nutraveda (ANL) share price was ₹290.00 at the 28 Oct 2026 close; market capitalisation ₹210 Cr; sector Healthcare. In the Mar 2026 quarter, revenue rose 80.1% year on year to ₹19.54 Cr and net profit rose 56.4% year on year to ₹2.69 Cr (compared with Mar 2025). Promoters held 73.48% of Accretion Nutraveda in Sep 2026, unchanged from Jun 2026.
Key Fundamentals
SMEPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of 28 Oct 2026, 15:30 IST · TTM
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,766.10 | 35.03 | 4,23,747 Cr | 5.07 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,626.00 | 87.37 | 2,55,540 Cr | 15.25 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,596.10 | 72.15 | 1,74,821 Cr | 9.51 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,183.80 | 107.90 | 1,17,993 Cr | 22.26 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,180.50 | 26.27 | 1,17,755 Cr | 4.34 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,340.80 | 34.73 | 1,11,914 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,370.90 | 32.84 | 1,10,749 Cr | 3.13 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Accretion Nutraveda (this company) | — | — | 210 Cr | 5.92 | 0.00% | 14.29% | 17.18% | — | — |
| Median 8 companies | ₹1,766.10 | 35.03 | 1,17,874 Cr | 5.50 | 0.47% | 14.04% | 17.56% | 28,515 Cr | 3,184 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100. How it works →
No Tapetide Score has been computed for this stock yet.
Key Insights
Strengths
1- Company has a good return on equity (ROE) track record: 3 Years ROE 35.0%
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 60.3 to 88.1 days.
- Working capital days have increased from 111 days to 196 days
Technical Indicators
Oscillators
Bearish
Overall
Bullish
Moving Averages
Bullish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 18.22% · Mar 2026
Quarterly Results
| Particulars | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 10.85 | 14.06 | 19.54 |
| Expenses | 8.27 | 10.76 | 15.98 |
| Operating Profit | 2.58 | 3.3 | 3.56 |
| OPM % | 23.78% | 23.47% | 18.22% |
| Other Income | 0 | 0 | 0.11 |
| Interest | 0.26 | 0.26 | 0.27 |
| Depreciation | 0.11 | 0.17 | 0.1 |
| PBT | 2.21 | 2.87 | 3.3 |
| Tax % | 22.17% | 18.47% | 18.48% |
| Net Profit | 1.72 | 2.33 | 2.69 |
| EPS (₹) | 3.51 | 4.38 | 3.72 |
Profit & Loss
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 2.89 | 5.01 | 16 | 33.59 |
| Expenses | 2.27 | 3.78 | 12.29 | 26.7 |
| Operating Profit | 0.62 | 1.23 | 3.71 | 6.89 |
| OPM % | 21.45% | 24.55% | 23.19% | 20.51% |
| Other Income | 0.17 | 0.19 | 0.01 | 0.11 |
| Interest | 0.19 | 0.24 | 0.35 | 0.53 |
| Depreciation | 0.31 | 0.26 | 0.22 | 0.26 |
| PBT | 0.29 | 0.92 | 3.15 | 6.21 |
| Tax % | 3.45% | 9.78% | 20.63% | 18.36% |
| Net Profit | 0.28 | 0.82 | 2.5 | 5.07 |
| EPS (₹) | 0.78 | 2.28 | 5.1 | 7 |
| Div. Payout % | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 0.36 | 0.36 | 0.49 | 7.24 |
| Reserves | -0.1 | 0.72 | 4.56 | 28.23 |
| Borrowings | 1.97 | 2.17 | 3.86 | 4.23 |
| Other Liabilities | 1.83 | 1.39 | 1.63 | 2.08 |
| Total Liabilities | 4.06 | 4.64 | 10.54 | 41.78 |
| Fixed Assets | 1.49 | 1.28 | 1.83 | 1.66 |
| CWIP | 0 | 0.1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets | 2.57 | 3.26 | 8.71 | 40.12 |
| Total Assets | 4.06 | 4.64 | 10.54 | 41.78 |
Cash Flow
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating | 0.68 | 0.23 | -2.22 | -9.42 |
| Investing | -0.01 | -0.16 | -0.87 | -14.5 |
| Financing | -0.63 | -0.04 | 2.98 | 25.19 |
| Net Cash Flow | 0.04 | 0.03 | -0.1 | 1.26 |
| Free Cash Flow | 0.67 | 0.07 | -3.09 | -15.45 |
| CFO/EBITDA | 110 | 27 | -42 | -113 |
Ratios
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | 101 | 18.21 | 74.6 | 88.13 |
| Inventory Days | 279 | 304 | 159 | 136 |
| Days Payable | 354 | 114 | 30.73 | 11.35 |
| Cash Conversion Cycle | 25.89 | 208 | 202 | 213 |
| Working Capital Days | 8.84 | 7.29 | 129 | 196 |
| ROCE % | — | 42.34% | 57.57% | 27.73% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Accretion Nutraveda insights
53 extracted metrics + investor summaries across FY23–FY26.
Documents
Frequently Asked Questions about Accretion Nutraveda
What does Accretion Nutraveda Ltd do?
Where is Accretion Nutraveda Ltd (ANL) listed?
Which sector does Accretion Nutraveda Ltd belong to?
What is the market capitalisation of Accretion Nutraveda Ltd?
What is the 52-week high and low of Accretion Nutraveda Ltd?
What is the Return on Equity (ROE) of Accretion Nutraveda Ltd?
Company Information
Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and Nutraceutical products in various dosage forms.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/544694.md for Accretion Nutraveda Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.